Fig. 5: Tyrosine kinase inhibitors (TKIs) identified as the most synergistic compounds in combination with NCK to reduce MDA-MB-231 cell survival. | npj Precision Oncology

Fig. 5: Tyrosine kinase inhibitors (TKIs) identified as the most synergistic compounds in combination with NCK to reduce MDA-MB-231 cell survival.

From: Vertical pathway inhibition of receptor tyrosine kinases and BAD with synergistic efficacy in triple negative breast cancer

Fig. 5

a Heatmap plot depicts cell viability of MDA-MB-231 cells post-treatment as % Fraction affected (Fa) (Scale: Green to Red). Fa was calculated as 100 - cell viability (%). b Fold change (FC) of cell viability after treatments (compound X versus compound X + 10 μM NCK) and Fa of compound X alone were plotted. Compounds were marked in different colors, each representing the pathway targeted by the compound. Compounds with average CI < 1 when co-treated with NCK are shown. CI was calculated using the bliss independence method (CI= (EA + EB-EAEB)/EAB), where CI < 1 denotes synergy. c Top pathways and targets synergizing with NCK are plotted. d Cell viability of MDA-MB-231 cells after treatment with the highly ranked synergistic TKIs (at their respective IC25) with/without 10 μM NCK (from drug screening assay). Data represent means ± SD. *P < 0.05, **P < 0.01, and ***P < 0.001.

Back to article page